Drugs / HPP737
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04714294 | Sep 2020 → May 2021 | — | Newsoara Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07707141 | Mar → Dec 2021 | psoriasis | Newsoara Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07712731 | Apr 2025 → Apr 2026 | psoriasis | Newsoara Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT07712705 | Apr → Sep 2023 | psoriasis | Newsoara Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06584058 | Aug 2024 → Jul 2025 overdue | psoriasis | Newsoara Biopharma Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPP737 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06584058 ↗ |
| Action | Inhibit | “HPP737 as an oral PDE4 inhibitor” NCT04714294 ↗ |
| Route | Oral | “taken orally (by mouth)” NCT04714294 ↗ |
| Target | PDE4B | “HPP737 is designed to preferentially inhibit PDE4B” NCT07712731 ↗ |